DOR BioPharma, Inc. (DORB) Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SGNX'
9/30/2009 10:40:23 AM
More...
|
DOR BioPharma, Inc. (DORB) Announces Private Equity Financing of $3.85 Million
9/24/2009 11:38:55 AM
More...
|
DOR BioPharma, Inc. (DORB) Announces National Institutes of Health (NIH) Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
9/8/2009 8:42:34 AM
More...
|
DOR BioPharma, Inc. (DORB) Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
8/14/2009 8:18:25 AM
More...
|
DOR BioPharma, Inc. (DORB) Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
7/8/2009 10:34:45 AM
More...
|
DOR BioPharma, Inc. (DORB) Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller Company
7/7/2009 10:41:32 AM
More...
|
DOR BioPharma, Inc. (DORB) Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6/9/2009 10:13:51 AM
More...
|
DOR BioPharma, Inc. (DORB) Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
5/15/2009 10:38:08 AM
More...
|
DOR BioPharma, Inc. (DORB) Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
3/31/2009 9:15:41 AM
More...
|
DOR BioPharma, Inc. (DORB) Executes $400,000 Equity Investment Agreement With Numoda Corporation
3/25/2009 10:35:40 AM
More...
|
|